https://www.selleckchem.com/pr....oducts/solutol-hs-15
There is a high demand for bladder sparing therapies in patients who do not respond to bacillus Calmette-Guérin (BCG). To report the mid-term results of intravesical gemcitabine in non-muscle-invasive bladder cancer (NMIBC) patients, who failed BCG and who were unwilling to undergo radical cystectomy (RC). This is an extended confirmatory open-label, single-arm study, which enrolled consecutive patients who failed BCG or were BCG intolerant and unwilling to undergo the RC (histologically confirmed Tis (CIS), T1 high grade or multi
Like
Comment
Share
